VENXXIVA

Manufacturer
Cycle Pharmaceuticals Ltd. | Optimus Pharma Private Limited
Effective date
2025-12-22
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
full-release
Hydrated at
2026-05-31 21:52:12

Label at a glance#

ProductVENXXIVA
Active ingredientTIOPRONIN
Label structure15 sections

Indications and uses

VENXXIVA is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 9 years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone. Additional pediatric use information is approved for Mission Pharmacal Company’s Thiola EC (tiopronin delayed-release) tablets. However, ...

Dosage and administration

Adults : The recommended initial dosage in adult patients is 800 mg/day. In clinical studies, the average dosage was about 1,000 mg/day. Pediatrics : The recommended initial dosage in pediatric patients 9 years of age and older is 15 mg/kg/day.  Avoid dosages greater than 50 mg/kg per day in pediatric patients  [see Warnings and Precautions ( 5.1 ), Use in Specific Populations ( 8.4 )] . Administer VENXXIVA in 3 d...

Storage and handling

100 mg delayed-release, white to off-white, round shaped, enteric-coated tablets imprinted with "1A" with black ink on one side and plain on other side, free from physical defects. Bottles of 300 with child-resistant closure, NDC  70709-121-30. 300 mg delayed-release, white to off-white, round shaped, enteric-coated tablets imprinted with "3A" with black ink on one side and plain on other side, free from physical ...

Label contents#

Full prescribing information#

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

VENXXIVA is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 9 years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone.

Additional pediatric use information is approved for Mission Pharmacal Company’s Thiola EC (tiopronin delayed-release) tablets. However, due to Mission Pharmacal Company’s marketing exclusivity rights, this drug product is not labeled with that information.

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

2.3 Monitoring

SPL UNCLASSIFIED SECTION

Measure urinary cystine 1 month after starting VENXXIVA and every 3 months thereafter. Adjust VENXXIVA dosage to maintain urinary cystine concentration less than 250 mg/L.

Assess for proteinuria before treatment and every 3 to 6 months during treatment [see Warnings and Precautions (5.1)].

Discontinue VENXXIVA in patients who develop proteinuria, and monitor urinary protein and renal function. Consider restarting VENXXIVA treatment at a lower dosage after resolution of proteinuria.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

Tablets for oral use:
100 mg tablets: White to off-white, round shaped, enteric coated tablets imprinted with "1A" with black ink on one side and plain on other side, free from physical defects.
300 mg tablets: White to off-white, round shaped, enteric coated tablets imprinted with "3A" with black ink on one side and plain on other side, free from physical defects.

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

VENXXIVA is contraindicated in patients with hypersensitivity to tiopronin or any other components of VENXXIVA [see Warnings and Precautions (5.2)].

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Proteinuria

SPL UNCLASSIFIED SECTION

Proteinuria, including nephrotic syndrome, and membranous nephropathy, have been reported with tiopronin use. Pediatric patients receiving greater than 50 mg/kg of tiopronin per day may be at increased risk for proteinuria. [see Dosage and Administration (2.3), Adverse Reactions (6.1, 6.2), Use in Specific Populations (8.4)]. Monitor patients for the development of proteinuria and discontinue therapy in patients who develop proteinuria [see Dosage and Administration (2.3)].

5.2 Hypersensitivity Reactions

SPL UNCLASSIFIED SECTION

Hypersensitivity reactions (drug fever, rash, fever, arthralgia and lymphadenopathy) have been reported [see Contraindications (4)].

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following adverse reactions are discussed in greater detail in other sections of the labeling:

  • Proteinuria [see Warnings and Precautions (5.1)]
  • Hypersensitivity [see Warnings and Precautions (5.2)]

6.1 Clinical Trials Experience

SPL UNCLASSIFIED SECTION

Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of the drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse reactions occurring at an incidence of ≥5% in an uncontrolled trial in 66 patients with cystinuria age 9 to 68 years are shown in the table below. Patients in group 1 had previously been treated with d-penicillamine; those in group 2 had not. Of those patients who had stopped taking d-penicillamine due to toxicity (34 out of 49 patients in group 1), 22 were able to continue treatment with tiopronin. In those without prior history of d-penicillamine treatment, 6% developed reactions of sufficient severity to require tiopronin withdrawal.

Table 1 presents adverse reactions ≥5% in either treatment group occurring in this trial.

Table 1: Adverse Reactions Occurring in One or More Patients

System Organ Class

Adverse Reaction 

Group 1

Previously treated

with

d-penicillamine

(N = 49)

Group 2

Naïve to

d-penicillamine

(N = 17)

Blood and Lymphatic System Disorders

anemia 

1 (2%)

1 (6%)

Gastrointestinal Disorders

nausea

12 (25%)

2 (12%)

emesis

5 (10%)

–

diarrhea/soft stools 

9 (18%)

1 (6%)

abdominal pain

–

1 (6%)

oral ulcers

6 (12%)

3 (18%)

General Disorders and Administration Site Conditions

fever

4 (8%)

–

weakness

2 (4%)

2 (12%)

fatigue

7 (14%)

–

peripheral (edema)

3 (6%)

1 (6%)

chest pain

–

1 (6%)

Metabolism and Nutrition Disorders

anorexia

4 (8%)

–

Musculoskeletal and Connective Tissue Disorders

arthralgia

–

2 (12%)

Renal and Urinary Disorders

proteinuria 

5 (10%)

1 (6%)

impotence

–

1 (6%)

Respiratory, Thoracic and Mediastinal Disorders

cough 

–

1 (6%)

Skin and Subcutaneous Tissue Disorders

rash

7 (14%)

2 (12%)

ecchymosis 

3 (6%)

–

pruritus

2 (4%)

1 (6%)

urticaria

4 (8%)

–

skin wrinkling 

3 (6%)

1 (6%)

Taste Disturbance

A reduction in taste perception may develop. It is believed to be the result of chelation of trace metals by tiopronin. Hypogeusia is often self-limited.

6.2 Postmarketing Experience

SPL UNCLASSIFIED SECTION

Adverse reactions have been reported from the literature, as well as during post-approval use of tiopronin. Because the post-approval reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to tiopronin exposure.

Adverse reactions reported during the postmarketing use of tiopronin are listed by body system in Table 2.

Table 2: Adverse Reactions Reported for Tiopronin Pharmacovigilance by System Organ Class and Preferred Term

System Organ Class 

Preferred Term

Cardiac Disorders

congestive heart failure

Ear and Labyrinth Disorder

vertigo

Gastrointestinal Disorders

abdominal discomfort; abdominal distension; abdominal pain; chapped lips; diarrhea; dry mouth; dyspepsia; eructation; flatulence; gastrointestinal disorder; gastroesophageal reflux disease; nausea; vomiting; jaundice; liver transaminitis

General Disorders and Administration Site Conditions

asthenia; chest pain; fatigue; malaise; pain; peripheral swelling; pyrexia; swelling

Investigations

glomerular filtration rate decreased; weight increased

Metabolism and Nutrition Disorders

decreased appetite; dehydration; hypophagia

Musculoskeletal and Connective Tissue Disorders

arthralgia; back pain; flank pain; joint swelling; limb discomfort; musculoskeletal discomfort; myalgia; neck pain; pain in extremity

Nervous System Disorders

ageusia; burning sensation; dizziness; dysgeusia; headache; hypoesthesia

Renal and Urinary Disorders

nephrotic syndrome; proteinuria; renal failure

Skin and Subcutaneous Tissue Disorders

dry skin; hyperhidrosis; pemphigus foliaceus; pruritus; rash; rash pruritic; skin irritation; skin texture abnormal; skin wrinkling; urticaria

7 DRUG INTERACTIONS

DRUG INTERACTIONS SECTION

7.1 Alcohol

SPL UNCLASSIFIED SECTION

Tiopronin is released faster from VENXXIVA in the presence of alcohol and the risk for adverse events associated with VENXXIVA when taken with alcohol is unknown. Avoid alcohol consumption 2 hours before and 3 hours after taking VENXXIVA [see Clinical Pharmacology (12.3)].

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

Risk Summary
Available published case report data with tiopronin have not identified a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Renal stones in pregnancy may result in adverse pregnancy outcomes (see Clinical Considerations). In animal reproduction studies, there were no adverse developmental outcomes with oral administration of tiopronin to pregnant mice and rats during organogenesis at doses up to 2 times a 2 grams/day human dose (based on mg/m2). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively.

Clinical Considerations
Disease-associated maternal and/or embryo/fetal risk
Renal stones in pregnancy may increase the risk of adverse pregnancy outcomes, such as preterm birth and low birth weight.

Data
Animal Data
No findings of fetal malformations could be attributed to the drug in reproduction studies in mice and rats at doses up to 2 times the highest recommended human dose of 2 grams/day (based on mg/m2).

8.2 Lactation

LABOR & DELIVERY SECTION

Risk Summary
There are no data on the presence of tiopronin in either human or animal milk or on the effects of the breastfed child. A published study suggests that tiopronin may suppress milk production. Because of the potential for serious adverse reactions, including nephrotic syndrome, advise patients that breastfeeding is not recommended during treatment with VENXXIVA.

8.4 Pediatric Use

PEDIATRIC USE SECTION

VENXXIVA is indicated in pediatric patients 9 years of age and older with severe homozygous cystinuria, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation who are not responsive to these measures alone. This indication is based on safety and efficacy data from a trial in patients 9 years to 68 years of age and clinical experience. Proteinuria, including nephrotic syndrome, has been reported in pediatric patients. Pediatric patients receiving greater than 50 mg/kg tiopronin per day may be at greater risk [see Dosage and Administration (2.1, 2.3), Warnings and Precautions (5.1) and Adverse Reactions (6.1)] .

VENXXIVA tablets are not approved for use in pediatric patients weighing less than 20 kg or in pediatric patients unable to swallow tablets [see Dosage and Administration (2.1)].

Additional pediatric use information is approved for Mission Pharmacal Company’s Thiola EC (tiopronin delayed-release) tablets. However, due to Mission Pharmacal Company’s marketing exclusivity rights, this drug product is not labeled with that information.

8.5 Geriatric Use

GERIATRIC USE SECTION

This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

10 OVERDOSAGE

OVERDOSAGE SECTION

There is no information on overdosage with tiopronin.

11 DESCRIPTION

DESCRIPTION SECTION

VENXXIVA (tiopronin) delayed-release tablets are a reducing and cystine-binding thiol drug (CBTD) for oral use. Tiopronin is N‑(2‑Mercaptopropionyl) glycine and has the following structure:

image descriptionimage description

Tiopronin has the empirical formula C5H9NO3S and a molecular weight of 163.19. In this drug product tiopronin exists as a dl racemic mixture.

Tiopronin is a white to off-white color crystalline powder, which is freely soluble in water.

Each VENXXIVA tablet contains 100 or 300 mg of tiopronin. The inactive ingredients in VENXXIVA tablets include lactose monohydrate, low substitute hydroxypropyl cellulose, hydroxypropyl cellulose, magnesium stearate, hypromellose 2910, methacrylic acid: ethyl acrylate copolymer (Eudragit L 100-55), talc, triethyl citrate. The imprinting ink contains shellac, ferrosoferric oxide and propylene glycol.

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

The goal of therapy is to reduce urinary cystine concentration below its solubility limit. Tiopronin is an active reducing agent which undergoes thiol-disulfide exchange with cystine to form a mixed disulfide of tiopronin-cysteine. From this reaction, a water-soluble mixed disulfide is formed and the amount of sparingly soluble cystine is reduced.

12.2 Pharmacodynamics

PHARMACODYNAMICS SECTION

The decrement in urinary cystine produced by tiopronin is generally proportional to the dose. A reduction in urinary cystine of 250 to 350 mg/day at tiopronin dosage of 1 g/day, and a decline of approximately 500 mg/day at a dosage of 2 g/day, might be expected. Tiopronin has a rapid onset and offset of action, showing a fall in cystine excretion on the first day of administration and a rise on the first day of drug withdrawal.

12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

Absorption
VENXXIVA Tablets
When tiopronin IR and VENXXIVA single doses were given to fasted healthy subjects, the median time to peak plasma levels (Tmax) was 1 (range: 0.5 to 2.1) and 3 (range: 1.0 to 6.0) hours, respectively. The peak exposure (Cmax) and total exposure (AUC0-t) of tiopronin from VENXXIVA tablets were decreased by 22% and 7% respectively compared to tiopronin IR tablets.

Elimination

Excretion
When tiopronin is given orally, up to 48% of dose appears in urine during the first 4 hours and up to 78% by 72 hours.

Drug Interactions
Alcohol
An in vitro dissolution study was conducted to evaluate the impact of alcohol (5, 10, 20, and 40%) on the dose dumping of VENXXIVA tablets. The study results showed that the addition of alcohol to the dissolution media increases the dissolution rate of VENXXIVA tablets in the acidic media of 0.1N HCl [see Drug Interactions (7.1)].

13 NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Carcinogenesis
Long-term carcinogenicity studies in animals have not been performed.

Mutagenesis
Tiopronin was not genotoxic in the chromosomal aberration, sister chromatid exchange, and in vivo micronucleus assays.

Impairment of Fertility
High doses of tiopronin in experimental animals have been shown to interfere with maintenance of pregnancy and viability of the fetus. In 2 published male fertility studies in rats, tiopronin at 20 mg/kg/day intramuscular (IM) for 60 days induced reductions in testis, epididymis, vas deferens, and accessory sex glands weights and in the count and motility of cauda epididymal sperm.

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

100 mg delayed-release, white to off-white, round shaped, enteric-coated tablets imprinted with "1A" with black ink on one side and plain on other side, free from physical defects.
Bottles of 300 with child-resistant closure, NDC 70709-121-30.

300 mg delayed-release, white to off-white, round shaped, enteric-coated tablets imprinted with "3A" with black ink on one side and plain on other side, free from physical defects.
Bottles of 90 with child-resistant closure, NDC 70709-123-90.

Store at 25°C (77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].

17 PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

Lactation

Advise women that breastfeeding is not recommended during treatment with VENXXIVA [see Use in Specific Populations (8.2)].

Manufactured for:

Torrent Pharmaceuticals Limited, India

logologo

Distributed by:
Cycle Pharmaceuticals Ltd, Cambridge, CB3 0FA, UK

Revised: December 2024

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

100 mg - 300 Tablets

image descriptionimage description

300 mg - 90 Tablets

image descriptionimage description

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
2178075tiopronin 100 MG Delayed Release Oral TabletPSN2
2178079tiopronin 300 MG Delayed Release Oral TabletPSN2
2702682VENXXIVA 100 MG Delayed Release Oral TabletPSN2
2702684VENXXIVA 300 MG Delayed Release Oral TabletPSN2
2702682tiopronin 100 MG Delayed Release Oral Tablet [Venxxiva]SBD2
2702684tiopronin 300 MG Delayed Release Oral Tablet [Venxxiva]SBD2
2178075tiopronin 100 MG Delayed Release Oral TabletSCD2
2178079tiopronin 300 MG Delayed Release Oral TabletSCD2
2702682Venxxiva 100 MG Delayed Release Oral TabletSY2
2702684Venxxiva 300 MG Delayed Release Oral TabletSY2

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
TIOPRONIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
BarcodeEAN-130370709121307GTIN-13: 0370709121307
EAN-13: 0370709121307
GTIN-12: 370709121307
UPC-A: 370709121307
GTIN storage (14 digits): 00370709121307
tiopronintablets-100mg-300t.jpg
BarcodeEAN-130370709123905GTIN-13: 0370709123905
EAN-13: 0370709123905
GTIN-12: 370709123905
UPC-A: 370709123905
GTIN storage (14 digits): 00370709123905
tiopronintablets-300mg-90t.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
19fd197c-a0a2-47ec-a473-bf965abd1795Product name220250429
594e2c86-3079-4e6e-96c9-48f7a8afc78dProduct name120230718
a6c2b4b8-5194-92f1-e438-706fc5c2e8b4Product name320230303

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
70709-121-30VENXXIVA300 in 1 BOTTLETABLET, DELAYED RELEASE3002
70709-123-90VENXXIVA90 in 1 BOTTLETABLET, DELAYED RELEASE902

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
70709-121-30EA - Each70709-121e7aaaaa7-7615-4568-8d5e-1e653f7a8e7412025-02-10
70709-123-90EA - Each70709-1236eac269d-deae-43ef-9384-c28601d4231b12025-02-10

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 10 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
70709-12170709-121-30
70709-12370709-123-90

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 18 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A216990-001VENXXIVATIOPRONIN100MGTABLET, DELAYED RELEASE / ORALAB2024-01-30
A216990-002VENXXIVATIOPRONIN300MGTABLET, DELAYED RELEASE / ORALAB2024-01-30

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 2 matching rows.

Application-product, TE code table
Application-productTE code
A216990-001AB
A216990-002AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 42 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A216990-001VENXXIVA100MGTABLET, DELAYED RELEASE / ORALAB2024-01-30d4dbc9d85df4…
2026-11-14 07:37:172026-10A216990-002VENXXIVA300MGTABLET, DELAYED RELEASE / ORALAB2024-01-30d4dbc9d85df4…
2026-10-15 13:18:302026-09A216990-001VENXXIVA100MGTABLET, DELAYED RELEASE / ORALAB2024-01-30c2088c7a36db…
2026-10-15 13:18:302026-09A216990-002VENXXIVA300MGTABLET, DELAYED RELEASE / ORALAB2024-01-30c2088c7a36db…
2026-09-14 22:38:342026-08A216990-001VENXXIVA100MGTABLET, DELAYED RELEASE / ORALAB2024-01-3084e616aacf4f…
2026-09-14 22:38:342026-08A216990-002VENXXIVA300MGTABLET, DELAYED RELEASE / ORALAB2024-01-3084e616aacf4f…
2026-08-18 06:07:402026-07A216990-001VENXXIVA100MGTABLET, DELAYED RELEASE / ORALAB2024-01-30caaa826d4ba7…
2026-08-18 06:07:402026-07A216990-002VENXXIVA300MGTABLET, DELAYED RELEASE / ORALAB2024-01-30caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A216990-001VENXXIVA100MGTABLET, DELAYED RELEASE / ORALAB2024-01-30011fe1cb6892…
2026-02-19 14:30 UTC2026-02A216990-002VENXXIVA300MGTABLET, DELAYED RELEASE / ORALAB2024-01-30011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A216990-001VENXXIVA100MGTABLET, DELAYED RELEASE / ORALAB2024-01-3031067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A216990-002VENXXIVA300MGTABLET, DELAYED RELEASE / ORALAB2024-01-3031067a03dcf5…
2025-08-23 18:47 UTC2025-08A216990-001TIOPRONIN100MGTABLET, DELAYED RELEASE / ORALAB2024-01-306a471c1ec25d…
2025-08-23 18:47 UTC2025-08A216990-002TIOPRONIN300MGTABLET, DELAYED RELEASE / ORALAB2024-01-306a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A216990-001TIOPRONIN100MGTABLET, DELAYED RELEASE / ORALAB2024-01-30fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A216990-002TIOPRONIN300MGTABLET, DELAYED RELEASE / ORALAB2024-01-30fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A216990-001TIOPRONIN100MGTABLET, DELAYED RELEASE / ORALAB2024-01-30b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A216990-002TIOPRONIN300MGTABLET, DELAYED RELEASE / ORALAB2024-01-30b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A216990-001TIOPRONIN100MGTABLET, DELAYED RELEASE / ORALAB2024-01-3003ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A216990-002TIOPRONIN300MGTABLET, DELAYED RELEASE / ORALAB2024-01-3003ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A216990-001TIOPRONIN100MGTABLET, DELAYED RELEASE / ORALAB2024-01-302680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A216990-002TIOPRONIN300MGTABLET, DELAYED RELEASE / ORALAB2024-01-302680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A216990-001TIOPRONIN100MGTABLET, DELAYED RELEASE / ORALAB2024-01-305bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A216990-002TIOPRONIN300MGTABLET, DELAYED RELEASE / ORALAB2024-01-305bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A216990-001TIOPRONIN100MGTABLET, DELAYED RELEASE / ORALAB2024-01-30d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A216990-002TIOPRONIN300MGTABLET, DELAYED RELEASE / ORALAB2024-01-30d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A216990-001TIOPRONIN100MGTABLET, DELAYED RELEASE / ORALAB2024-01-30d06236e962d9…
2024-10-29 15:01 UTC2024-10A216990-002TIOPRONIN300MGTABLET, DELAYED RELEASE / ORALAB2024-01-30d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A216990-001TIOPRONIN100MGTABLET, DELAYED RELEASE / ORALAB2024-01-3079d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A216990-002TIOPRONIN300MGTABLET, DELAYED RELEASE / ORALAB2024-01-3079d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A216990-001TIOPRONIN100MGTABLET, DELAYED RELEASE / ORALAB2024-01-30301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A216990-002TIOPRONIN300MGTABLET, DELAYED RELEASE / ORALAB2024-01-30301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A216990-001TIOPRONIN100MGTABLET, DELAYED RELEASE / ORALAB2024-01-301e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A216990-002TIOPRONIN300MGTABLET, DELAYED RELEASE / ORALAB2024-01-301e350fbaab3a…
2024-05-31 18:47 UTC2024-05A216990-001TIOPRONIN100MGTABLET, DELAYED RELEASE / ORALAB2024-01-308072bd15b7f6…
2024-05-31 18:47 UTC2024-05A216990-002TIOPRONIN300MGTABLET, DELAYED RELEASE / ORALAB2024-01-308072bd15b7f6…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A216990-001TIOPRONIN100MGTABLET, DELAYED RELEASE / ORALAB2024-01-306a51e52b5d6a…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A216990-002TIOPRONIN300MGTABLET, DELAYED RELEASE / ORALAB2024-01-306a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A216990-001TIOPRONIN100MGTABLET, DELAYED RELEASE / ORALAB2024-01-301c564ffb4f44…
2024-02-18 07:12 UTC2024-02A216990-002TIOPRONIN300MGTABLET, DELAYED RELEASE / ORALAB2024-01-301c564ffb4f44…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 42 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A216990-001AB1d4dbc9d85df4…
2026-11-14 07:37:172026-10A216990-002AB1d4dbc9d85df4…
2026-10-15 13:18:302026-09A216990-001AB1c2088c7a36db…
2026-10-15 13:18:302026-09A216990-002AB1c2088c7a36db…
2026-09-14 22:38:342026-08A216990-001AB184e616aacf4f…
2026-09-14 22:38:342026-08A216990-002AB184e616aacf4f…
2026-08-18 06:07:402026-07A216990-001AB1caaa826d4ba7…
2026-08-18 06:07:402026-07A216990-002AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A216990-001AB1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A216990-002AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A216990-001AB131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A216990-002AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08A216990-001AB16a471c1ec25d…
2025-08-23 18:47 UTC2025-08A216990-002AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A216990-001AB1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A216990-002AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A216990-001AB1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A216990-002AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A216990-001AB103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A216990-002AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A216990-001AB12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A216990-002AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A216990-001AB15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A216990-002AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A216990-001AB1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A216990-002AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A216990-001AB1d06236e962d9…
2024-10-29 15:01 UTC2024-10A216990-002AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A216990-001AB179d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A216990-002AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A216990-001AB1301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A216990-002AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A216990-001AB11e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A216990-002AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A216990-001AB18072bd15b7f6…
2024-05-31 18:47 UTC2024-05A216990-002AB18072bd15b7f6…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A216990-001AB16a51e52b5d6a…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A216990-002AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A216990-001AB11c564ffb4f44…
2024-02-18 07:12 UTC2024-02A216990-002AB11c564ffb4f44…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
VENXXIVATIOPRONINCycle Pharmaceuticals Ltd.02e24443-04c6-4b98-a395-49aec4a468de2025-12-22Warnings, Adverse reactionsExact identifier
ndc (package): 70709-123-90
ndc (package): 70709-121-30
ndc (product): 70709-121
ndc (product): 70709-123
ndc11 (package): 70709012130
ndc11 (package): 70709012390
spl id: c8eeb4d4-9718-41ba-b4fe-3d645fd60a20
spl set id: 02e24443-04c6-4b98-a395-49aec4a468de

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.